Verve Therapeutics Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2020
Net Income	-15.26	-15.55	-17.9	-18.32	-20.69	-6.02	Upgrade
Other Operating Activities	0.1	-0	1.5	0.31	-	-	Upgrade
Change in Accounts Receivable	0.48	0.48	-0.13	-0.3	-0.35	0.53	Upgrade
Change in Other Net Operating Assets	-0.4	0.39	-0.15	-3.41	4.96	-1.74	Upgrade
Operating Cash Flow	-15.08	-14.68	-16.68	-21.72	-16.08	-7.23	Upgrade
Other Investing Activities	-	-	-	-	-0.05	-	Upgrade
Investing Cash Flow	-	-	-	-	-0.05	-	Upgrade
Short-Term Debt Issued	-	-	7	11.5	-	10.2	Upgrade
Total Debt Issued	-	-	7	11.5	-	10.2	Upgrade
Net Debt Issued (Repaid)	-	-	7	11.5	-	10.2	Upgrade
Issuance of Common Stock	-	-	19.37	-	33	3	Upgrade
Other Financing Activities	5	-	-1.05	-	-3.57	-	Upgrade
Financing Cash Flow	5	-	25.32	11.5	29.43	13.2	Upgrade
Net Cash Flow	-10.08	-14.68	8.64	-10.22	13.3	5.97	Upgrade
Cash Interest Paid	-	-	-	-	0	0	Upgrade
Levered Free Cash Flow	-9.48	-9.03	-11.32	-14.86	-8.32	-4.98	Upgrade
Unlevered Free Cash Flow	-9.42	-9.03	-10.38	-14.66	-8.32	-4.97	Upgrade
Change in Net Working Capital	-0.18	-0.87	0.13	3.41	-4.61	1.21	Upgrade

Updated Feb 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.